... I've got to admit I was hoping it would have been a committment to use the people from the IIB in the next trial.
I'm hoping that's just "understood" because for Opexa to have reliable post-trial data, they'll need as much participation as possible from the lab rats in Phases I and II and well as the new III.
Still, Tim mentioned that after .....5 treatments? the hope was that the myelin reactive T cells and the B cells creating them would be eliminated and I have to admit that they were just barely able to find what they needed to make the treatment going into the IIB.
That would push Tovaxin into the "cure" category rather than "treatment." It was my understanding that during future trials and once the gunk comes to market, we'll be schlepping hither and yon for our five treatments annually.
She hasn't been to a neuro since the IIB ended and we've seen no reason to think that anything is going on with the MS but knowing you have MS and knowing what it is capable of and going as long as she has without doing anything about it is making her feel pretty unprotected and there is no doubt that she'd like to be back under the wings of Opexa again.
I know what you mean! I'm still learning to deal with the "numb thumb" and think this will be permanent deficit. So I'm not warm and fuzzy about "other stuff" and really getting seriously impatient about the next step. Grrr.